Skip to content
Back to meeting Original
METCrusaders· @metcrusaders · X·· 9 hours agoScore70

SANOVO

Body

#ESMO26 | Dr. Rebecca Heist (@MGHThoracicOnc): Is MET testing the next step in personalized lung cancer treatment?
SANOVO showed improved median PFS (24.9 vs 13.8 months) with savolitinib + osimertinib in EGFR-mutated, MET-overexpressing NSCLC. Could MET guide first-line treatment selection?

#METCrusaders #NSCLC #LungCancer #SANOVO #PrecisionMedicine #lcsm

8 views · 0 likes · 0 reposts · 0 replies

Source: METCrusaders · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.